Phase 2 Asthma Trial, Recruiting NCT06216535 Sponsor: University of Texas Southwestern Medical Center Condition: Asthma
Back to Asthma

Phase 2 Asthma Trial, Recruiting

NCT06216535
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have moderate to severe persistent asthma
  • People who are currently being treated with medium to high doses of inhaled corticosteroids (preventer inhalers) combined with a long-acting bronchodilator (LABA)
  • People who have had three or more serious asthma attacks in the past year, where each attack required at least 3 days of steroid tablets or injections
  • People aged 18 to 75 years old, of any sex, who speak English or Spanish
  • People who have been medically stable for at least 4 weeks before joining — meaning no recent asthma attacks, infections, or changes to their asthma medications
  • People already taking a biologic medication for asthma (such as omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, or tezepelumab), provided that medication was started at least 6 months before entering the trial

Who may not be able to join:

  • People who currently have a substance use disorder, who currently smoke, or who have a smoking history of more than 10 pack-years across their lifetime
  • People who are currently experiencing a major depressive episode, or who have a diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder
  • People with an intellectual disability or severe cognitive impairment, people who are currently incarcerated, women who are pregnant or breastfeeding, or women of childbearing age who are not willing to use trial-approved contraception or abstinence during the study
  • People who are currently taking an antidepressant medication — although some exceptions may apply for certain medications prescribed for reasons other than depression at low doses (confirm with trial site)
  • People considered at high risk for suicide, defined as having had more than one suicide attempt in their lifetime, or any suicide attempt within the past 12 months
  • People with a severe or life-threatening medical condition that would make completing the trial unlikely, or who have significantly abnormal blood test or heart tracing (ECG) results at the start of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sherwood Brown, M.D, Ph.D, MBA, UTSW Medical Center

Phone: 214-645-6963

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
19 May 2025
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Total number of severe asthma exacerbations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov